What is Lakewood-Amedex Biotherapeutics Current Ratio?
Lakewood-Amedex BiotherapeuticsLABT +2.33%8 Current Ratio is 0.02 as of Mar. 2026, which is 94% below its 10-year median of 0.36. GuruFocus rates LABT with a GF Score™ of 8/100. Among 1,416 Biotechnology companies, Lakewood-Amedex Biotherapeutics ranks worse than 99.36% on this metric.
Lakewood-Amedex Biotherapeutics has a current ratio of 0.02. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Lakewood-Amedex Biotherapeutics has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Lakewood-Amedex Biotherapeutics's Current Ratio or its related term are showing as below:
LABT'
s Current Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.36 Max: 3.14
Current: 0.02
During the past 3 years, Lakewood-Amedex Biotherapeutics's highest Current Ratio was 3.14. The lowest was 0.02. And the median was 0.36.
LABT's Current Ratio is ranked worse than 99.36% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs LABT: 0.02
Lakewood-Amedex Biotherapeutics (NAS:LABT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lakewood-Amedex Biotherapeutics Current Ratio Related Terms
Lakewood-Amedex Biotherapeutics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics Current Ratio Chart
For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakewood-Amedex Biotherapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lakewood-Amedex Biotherapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics (LABT) has a Current Ratio of 0.02 as of Mar. 2026. This is 94% below median its historical median of 0.36. Over the past decade, Lakewood-Amedex Biotherapeutics' Current Ratio has ranged from 0.02 to 3.14. According to the industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #1407 out of 1416 companies in the Biotechnology industry, placing it in the top 99.4%.
Is Lakewood-Amedex Biotherapeutics' Current Ratio too high?
Lakewood-Amedex Biotherapeutics' current Current Ratio of 0.02 is 94% below median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 3.14. The Biotechnology industry median Current Ratio is 3.89. Lakewood-Amedex Biotherapeutics' value of 0.02 is 99.5% below this industry median. Based on the distribution chart, Lakewood-Amedex Biotherapeutics ranks #1407 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Current Ratio compare to CURX and PBM?
According to the Biotechnology industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #1407 out of 1416 companies for Current Ratio. This places Lakewood-Amedex Biotherapeutics in the lower half of its industry. The industry median Current Ratio is 3.89. Lakewood-Amedex Biotherapeutics' value of 0.02 is 99.5% below this benchmark. Historically, Lakewood-Amedex Biotherapeutics' own Current Ratio has ranged from 0.02 to 3.14 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 3.89, Lakewood-Amedex Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakewood-Amedex Biotherapeutics's current Current Ratio of 0.02 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakewood-Amedex Biotherapeutics's current Current Ratio is 0.02, which is 94% below median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Current Ratio of 0.02. The current Current Ratio is 0.02, which is 94% below median its 10-year median of 0.36 and 99.5% below the Biotechnology industry median of 3.89. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Current Ratio is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lakewood-Amedex Biotherapeutics Business Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score
Get the complete analysis for LABT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABT has been successfully added to your 